Cefadroxil

Product NDC: 0143-9767
11-digit product format: 001439767
Labeler code: 0143
Product ID: 0143-9767_ab8f4cac-f079-413d-82b0-cd1b2ef8a8f2
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Cefadroxil
Dosage form: POWDER, FOR SUSPENSION
Route: ORAL
Labeler: Hikma Pharmaceuticals USA Inc.
Application: ANDA091036
Marketing category: ANDA
Marketing start: 2012-11-28
Marketing end: 0000-00-00
Substance: CEFADROXIL
Active strength: 250 mg/5mL
Pharmacologic classes: Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
NDC exclude flag: No
Listing certified through: 2022-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 3 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	0143-9767		D	Discontinued by firm	2026-10-15
excluded package	package	0143-9767	0143-9767-01	D	Discontinued by firm	2026-10-15
excluded package	package	0143-9767	0143-9767-50	D	Discontinued by firm	2026-10-15

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 36 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0143-9767-01	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0143-9767-50	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0143-9767-01	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0143-9767-50	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0143-9767-01	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0143-9767-50	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0143-9767-01	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0143-9767-50	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0143-9767-01	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0143-9767-50	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0143-9767-01	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0143-9767-50	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0143-9767-01	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0143-9767-50	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0143-9767-01	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0143-9767-50	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0143-9767-01	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0143-9767-50	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0143-9767-01	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0143-9767-50	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0143-9767-01	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0143-9767-50	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0143-9767-01	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0143-9767-50	`557ba5c1ecfa…`	`9c80585c8c6e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
A091036-001	CEFADROXIL	CEFADROXIL/CEFADROXIL HEMIHYDRATE	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL			2012-11-28
A091036-002	CEFADROXIL	CEFADROXIL/CEFADROXIL HEMIHYDRATE	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL			2012-11-28

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL		2012-11-28	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	AB	2012-11-28	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	AB	2012-11-28	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	AB	2012-11-28	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	AB	2012-11-28	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	A091036-001	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	AB	2012-11-28	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	A091036-002	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	AB	2012-11-28	`4b0b4de00fa7…`

Observed Orange Book normalized TE history#

Normalized TE history page 2 of 2 · 48 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	A091036-001	AB	1	`3a93d1ddd44b…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	A091036-002	AB	1	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	A091036-001	AB	1	`f41ea6bd6efb…`
2022-10-28 04:53 UTC	2022-10	A091036-002	AB	1	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	A091036-001	AB	1	`e64feba35796…`
2022-09-29 23:25 UTC	2022-09	A091036-002	AB	1	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	A091036-001	AB	1	`cb3db0bc1861…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	A091036-002	AB	1	`cb3db0bc1861…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0143-9767-01	ML - Milliliter	0143-9767	1da1ca9e-c224-471d-9aa2-77847754d6cc	1	2016-10-06
0143-9767-50	ML - Milliliter	0143-9767	811b2f75-0da6-4b3e-8d2c-16c01b3b929c	1	2016-10-06

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CEFADROXIL	ACTIVE INGREDIENT	280111G160	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3
CEFADROXIL ANHYDROUS	ACTIVE MOIETY	Q525PA8JJB	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3
FD&C YELLOW NO. 6	INACTIVE INGREDIENT	H77VEI93A8	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3
POLYSORBATE 80	INACTIVE INGREDIENT	6OZP39ZG8H	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3
SUCROSE	INACTIVE INGREDIENT	C151H8M554	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3
XANTHAN GUM	INACTIVE INGREDIENT	TTV12P4NEE	CEFADROXIL POWDER, FOR SUSPENSION [WEST-WARD PHARMACEUTICAL CORP]	3

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
280111G160	CEFADROXIL	66592-87-8	CEFADROXIL

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
0143-9767-01	00143976701	100 mL in 1 BOTTLE (0143-9767-01)	100 ml	2012-11-28	0000-00-00	No	No	Current
0143-9767-50	00143976750	50 mL in 1 BOTTLE (0143-9767-50)	50 ml	2012-11-28	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
CEFADROXIL for Oral suspension, USP 250 mg/5 mL and 500 mg/5 mL Rev. 10/20 Rx only	Hikma Pharmaceuticals USA Inc.	2020-10-30	HUMAN PRESCRIPTION DRUG LABEL	6